Merck at The AAN

Posted in Industry News on 16th Apr 2018

 

Merck will be presenting data for MAVENCLAD® (Cladribine Tablets) a treatment for highly active relapsing multiple sclerosis (RMS) as defined by clinical or imaging features, and Rebif®(interferon beta-1a) at the American Academy of Neurology (AAN) 70th Annual Meeting, April 21-27, 2018, in Los Angeles.

MAVENCLAD® data to be presented includes poster presentations highlighting post-hoc analyses of the CLARITY, CLARITY Extension and ORACLE-MS trials evaluating safety and use in patients with multiple sclerosis (MS), as well as the impact on B- and T-cells. MAVENCLAD® is a short-course oral therapy that is thought to preferentially target lymphocytes which may be integral to the pathological process of relapsing forms of MS (RMS). MAVENCLAD® is currently under clinical investigation and is not approved in the US.

MAVENCLAD® has received marketing authorisation in 35 countries including European Union member countries, Canada, Australia, Argentina, Israel, and the United Arab Emirates. MAVENCLAD® is now available in Germany, UK, Canada, Netherlands, Norway, Denmark, Sweden, Israel, and other markets. The Company plans additional filings for regulatory approval in other countries, including the United States.

Rebif data includes presentations analysing no evidence of disease activity (NEDA), long-term disease activity assessed by the Magnetic Resonance Imaging in MS (MAGNIMS) score, new data on pregnancy outcomes for women being treated with interferon beta, as well as real-world evidence evaluating treatment adherence rates for patients treated with Rebif compared with dimethyl fumarate.

We look forward to presenting data demonstrating advancement in our knowledge of MS, including further scientific information about Mavenclad and Rebif at the 2018 AAN Annual Meeting

said Luciano Rossetti, Head of Global R&D for the biopharma business of Merck.

Meeting attendees can learn more about the Company and participate in the following MS-specific interactive activities by visiting booth #1847:

  • “I’m Balancing MS”: Individuals can understand the balance between healthcare and lifestyle for those facing MS through a mobile art activity. For each participant, we will donate $100 to MS Fitness Challenge, a charity organisation dedicated to educating and training people with MS on the benefits of exercise and nutrition.
  •  “Shine a Light”: Individuals can create their own Light Trail art symbolising what drives their commitment to fighting MS. Participation in the activity will drive a donation to MS Fitness Challenge.

Additionally, Exhibit Hall booth #1957 will host hands-on activities which will allow attendees to gain a better understanding of what it’s like to have MS through virtual reality pods and simulation stations.

The company will also be hosting an Industry Therapeutic Update event entitled Evolving Perspectives and Innovations in Multiple Sclerosis on Wednesday, April 25 from 7:00 p.m.-10:00 pm PDT at the Platinum Ballroom in the JW Marriott Hotel in Los Angeles. Speakers include, Professor Amit Bar-Or, University of Pennsylvania, Philadelphia, PA, Professor Dusan Stefoski, Rush University Medical Center, Chicago, IL and Professor Anthony Traboulsee, University of British Columbia, Vancouver, CA.

AAN Brain Health Fair

The MS InsideOut experience will be exhibited at the AAN Brain Health Fair, a one-day-only event where attendees can learn about the brain and the field of neurology. The event takes place on Friday, April 20 from 10:00 a.m.-4:00 pm PDT at the Los Angeles Convention Center.

Presentations at AAN 2018 include the following accepted abstracts:

Cladribine Tablets Presentations
Title Lead Author Abstract/Poster # Presentation Details
Effects of Cladribine Tablets on CD4+ T-cell Subsets in the ORACLE-MS

Study: Results from an Analysis of Lymphocyte Surface Markers

Leist T. 402 Session P1: Biomarkers and Experimental Studies for Multiple Sclerosis on

April 22, 2018

 

On Display: 11:30 a.m. to 5:30 p.m. PDT

 

Present: 4:00 p.m. to

5:30 p.m. PDT

Integrated Safety Analysis of Infections during Periods of Grade 3 or 4 Lymphopenia in Patients Taking Cladribine Tablets 3.5mg/kg Cook S. 407 Session P3: MS Therapeutics in Development on

April 24, 2018

 

On Display: 11:30 a.m. to 7:00 p.m. PDT

 

Present: 5:30 p.m. to

7:00 p.m. PDT

Effectiveness of Lymphocyte-based Re-treatment Criteria in

Minimizing the Incidence of Severe Sustained Lymphopenia During

Treatment with Cladribine Tablets 3.5mg/kg

Cook S. 370 Session P5: MS Therapies: MOA, Safety and Complications on

April 26, 2018

 

On Display: 11:30 a.m. to 7:00 p.m. PDT

 

Present: 5:30 p.m. to

7:00 p.m. PDT

Long-term Lymphocyte Counts in Patients with RRMS Treated with Cladribine Tablets 3.5 mg/kg: Total Lymphocytes, B-, and T-cell Subsets Soelberg-Sorensen P. 364 Session P5: MS Therapies: MOA, Safety and Complications on

April 26, 2018

 

On Display: 11:30 a.m. to 7:00 p.m. PDT

 

Present: 5:30 p.m. to 7:00 p.m. PDT

Selective and Discontinuous Reduction of B and T Lymphocytes and NK cells in Patients with Early and Relapsing MS (ORACLE-MS, CLARITY and CLARITY Extension) After Administration of Cladribine Tablets Stuve O. 351 Session P5: MS Therapies: MOA, Safety and Complications on

April 26, 2018

 

On Display: 11:30 a.m. to 7:00 p.m. PDT

 

Present: 5:30 p.m. to

7:00 p.m. PDT

Rebif® (interferon beta-1a) Presentations
Title Lead Author Abstract/Poster # Presentation Details
Relapse in Patients with Multiple Sclerosis Newly Initiating scIFNβ1a Compared with Oral Disease-Modifying Drugs: A Real-World Assessment Bowen J. 353 Session P1: Comparative Efficacy of Disease Modifying Therapies on April 22, 2018

 

On display: 11:30 a.m. to 5:30 p.m. PDT

 

Present: 4:00 p.m. to 5:30 p.m. PDT

A Panel Survey Analysis of Adherence in Patients with Multiple Sclerosis Treated with scIFNβ1a or Dimethyl Fumarate Perrin Ross A. 354 Session P1: Comparative Efficacy of Disease Modifying Therapies on April 22, 2018

 

On display: 11:30 a.m. to 5:30 p.m. PDT

 

Present: 4:00 p.m. to 5:30 p.m. PDT

Disease Activity as Assessed by the Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) Score Predicts Long-Term Clinical Disease Activity (CDA)-Free Status and

Disability Progression in Patients Treated with Subcutaneous Interferon beta-1a

(scIFNβ-1a)

Sormani M.P. 005 Session S24: MS

Outcome Measures and Biomarkers on April 24, 2018, 4:18 p.m.-4:30 p.m. PDT

Evolution of New Lesions and its Temporal Patterns in Patients with

Clinically Isolated Syndrome (CIS) Treated with Subcutaneous Interferon

beta-1a (scIFNß-1a)

Vrenken H. 370 Session P3: MS and CNS Inflammatory Disease: Neuroimaging on

April 24, 2018

 

On display: 11:30 a.m. to 7:00 p.m. PDT

 

Present: 5:30 p.m. to 7:00 p.m. PDT

Risk of Stroke in Patients with Multiple Sclerosis Treated with Subcutaneous Interferon beta-1a Sabidó-Espin M. 008 Session S36: MS Therapeutics and Clinical Research on April 25, 2018

 

4:54 p.m. to 5:06 p.m. PDT

Cumulative Data from the European Interferon Beta Pregnancy

Registry

Hellwig K. 357 Session P4: Pregnancy and Multiple Sclerosis on April 25, 2018

 

On display: 11:30 a.m. to 7:00 p.m. PDT

 

Present: 5:30 p.m. to 7:00 p.m. PDT

Impact of the Presence of Gadolinium-Enhancing (Gd+) Lesions at Baseline on No Evidence of Disease Activity (NEDA) Status in Patients Treated with Subcutaneous Interferon beta-1a (scIFNß-1a): A Post-hoc Analysis of REFLEXION Freedman M. 387 Session P6:  MS Therapeutics: Extension Studies on April 27, 2018

 

On display: 11:30 a.m. to 5:30 p.m. PDT

 

Present: 4:00 p.m. to 5:30 p.m. PDT

Analysis of 6-month Confirmed Disability Progression in RRMS

Patients Treated with Subcutaneous Interferon beta-1a

Wong S.L. 361 Session P6: MS Therapeutics III on April 27, 2018

 

On display:11:30 a.m. to 5:30 p.m. PDT

 

Present: 4:00 p.m. to 5:30 p.m. PDT

 

Full session details and data presentation listings for the 2018 AAN Annual Meeting can be found at the meeting website: https://www.aan.com/conferences-community/annual-meeting

SIGN UP FOR OUR MAILING LIST

Open Access, for medical professionals: Sign up to receive our email newsletter with links to the latest content. ACNR is free, thanks to the support of advertisers. The editorial content is peer reviewed and remains completely independent unless clearly specified. 

We may infrequently send you news from our sponsors which is relevant to the field of neurology, but you can opt out at any time.

This website is for medical professionals only.